Black Diamond Therapeutics, Inc. (BDTX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BDTX SEC filings page.
Black Diamond Therapeutics, Inc. (BDTX) reported $70.0M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
After years of cash use, FY2025 shows a revenue-generating business with positive operating profit and operating cash flow.
The shift from operating cash flow of-$66.7M in FY2023 to$29.6M in FY2025 is stronger than the accounting improvement alone: cash generation reached roughly42.3% of FY2025 revenue, while operating profit was$12.5M . That gap suggests cash conversion benefited from non-operating working-capital or timing effects, so reported profit does not fully explain the cash result.
FY2025 revenue was
The balance sheet became more conservative relative to FY2023: liabilities fell to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Black Diamond Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Black Diamond Therapeutics, Inc. held $128.7M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $29.6M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Black Diamond Therapeutics, Inc. scores 85/100 among other emerging companies.
Black Diamond Therapeutics, Inc. had 57M shares outstanding at the end of fiscal year 2025, against 57M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Black Diamond Therapeutics, Inc. scores 57/100 among other emerging companies.
Black Diamond Therapeutics, Inc. spent $33.6M on research and development in fiscal year 2025, which was 58.4% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Black Diamond Therapeutics, Inc. scores 81/100 among other emerging companies.
Not available for Black Diamond Therapeutics, Inc., and counted as zero in the overall score.
Black Diamond Therapeutics, Inc.'s operations generated $29.6M of cash in fiscal year 2025, against $62.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Black Diamond Therapeutics, Inc. scores 92/100 among other emerging companies.
Black Diamond Therapeutics, Inc.'s cash, cash equivalents and investments came to $128.7M at the end of fiscal year 2025, against $30.8M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Black Diamond Therapeutics, Inc. scores 87/100 among other emerging companies.
Black Diamond Therapeutics, Inc. scores -0.87, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($98.8M) relative to total liabilities ($30.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Key Financial Metrics
Earnings & Revenue
Black Diamond Therapeutics, Inc. generated $0 in revenue in Q2 2026.
Black Diamond Therapeutics, Inc.'s EBITDA was -$12.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 9.8% from the same quarter a year earlier. Against the prior quarter it is down 7.1%.
Black Diamond Therapeutics, Inc. reported -$9.9M in net income in Q2 2026. This represents an increase of 6.2% from the same quarter a year earlier. Against the prior quarter it is down 9.6%.
Black Diamond Therapeutics, Inc. earned -$0.17 per diluted share (EPS) in Q2 2026. This represents an increase of 10.5% from the same quarter a year earlier. Against the prior quarter it is down 6.3%.
Cash & Balance Sheet
Black Diamond Therapeutics, Inc. held $19.2M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Black Diamond Therapeutics, Inc.'s ROE was -10.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 2.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.7 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Black Diamond Therapeutics, Inc. invested $7.4M in research and development in Q2 2026. This represents a decrease of 20.7% from the same quarter a year earlier. Against the prior quarter it is up 5.6%.
Not reported for Q2 2026.
Not reported for Q2 2026.
BDTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0-100.0% | N/A | $0 | $0 | $70.0M | N/A | $0 |
| R&D Expenses | $7.4M-20.7% | $7.0M-33.3% | N/A | $7.4M-42.4% | $9.3M-25.8% | $10.5M-22.4% | N/A | $12.9M-20.1% |
| SG&A Expenses | $4.7M+13.7% | $4.3M-14.3% | N/A | $3.5M-32.1% | $4.1M-57.2% | $5.0M-25.9% | N/A | $5.2M-33.6% |
| Operating Income | -$12.1M+10.2% | -$11.3M-120.6% | N/A | -$11.0M+39.4% | -$13.4M+39.4% | $54.5M+369.3% | N/A | -$18.1M+24.5% |
| EBITDA | -$12.0M+9.8% | -$11.2M-120.6% | N/A | -$10.9M+39.6% | -$13.3M+39.5% | $54.6M+370.9% | N/A | -$18.0M+24.5% |
| Income Tax | N/A | N/A | N/A | N/A | N/A | $226K | N/A | N/A |
| Net Income | -$9.9M+6.2% | -$9.0M-116.0% | N/A | -$8.5M+45.4% | -$10.6M+47.0% | $56.5M+410.2% | N/A | -$15.6M+32.4% |
| EPS (Basic) | -$0.17+10.5% | -$0.16-116.0% | -$0.27+3.6% | -$0.15+46.4% | -$0.19+47.2% | $1.00+385.7% | -$0.28+17.6% | -$0.28+37.8% |
| EPS (Diluted) | -$0.17+10.5% | -$0.16-116.3% | -$0.26+7.1% | -$0.15+46.4% | -$0.19+47.2% | $0.98+380.0% | -$0.28+17.6% | -$0.28+37.8% |
| Diluted Shares (Avg) | 57M+1.0% | 57M-0.8% | N/A | 57M+0.7% | 57M+3.0% | 58M+11.3% | N/A | 57M+10.9% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
BDTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $125.0M-24.9% | $132.9M-24.6% | $143.0M+16.6% | $157.7M+14.4% | $166.4M+10.9% | $176.2M+23.7% | $122.6M-22.7% | $137.9M-20.0% |
| Current Assets | $115.4M-21.4% | $123.0M-21.0% | $132.4M+30.9% | $139.0M+20.3% | $146.7M+15.8% | $155.7M+31.0% | $101.2M-24.5% | $115.5M-21.4% |
| Cash & Equivalents | $19.2M-36.0% | $30.1M-69.4% | $21.0M-42.4% | $30.9M+31.8% | $30.0M-8.6% | $98.4M+287.2% | $36.4M-35.2% | $23.4M-59.6% |
| Short-Term Investments | $91.3M-19.1% | $88.2M+63.4% | $107.7M+73.3% | $104.6M+17.2% | $112.8M+25.2% | $54.0M-39.9% | $62.1M-17.3% | $89.3M+3.5% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $28.9M-14.3% | $28.6M-17.6% | $30.8M-21.7% | $31.6M-22.0% | $33.8M-13.3% | $34.7M-9.1% | $39.4M-5.9% | $40.5M+6.3% |
| Current Liabilities | $15.8M-5.7% | $14.5M-13.7% | $15.7M-23.5% | $15.5M-25.3% | $16.8M-8.9% | $16.8M0.0% | $20.6M+4.7% | $20.8M+38.1% |
| Non-Current Liabilities | $13.1M-22.8% | $14.1M-21.2% | $15.1M-19.8% | $16.0M-18.5% | $17.0M-17.3% | $17.9M-16.3% | $18.8M-15.3% | $19.7M-14.5% |
| Total Equity | $96.1M-27.5% | $104.3M-26.3% | $112.2M+34.7% | $126.2M+29.5% | $132.6M+20.0% | $141.5M+35.7% | $83.3M-28.7% | $97.4M-27.5% |
| Retained Earnings | -$483.7M-9.6% | -$473.8M-10.0% | -$464.7M+4.6% | -$449.6M+4.6% | -$441.1M+3.2% | -$430.6M+1.2% | -$487.1M-16.7% | -$471.1M-18.4% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
BDTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.0M+13.0% | -$10.2M-119.2% | -$6.8M+54.9% | -$7.8M+30.7% | -$9.2M+37.8% | $53.4M+351.9% | -$15.1M-7.9% | -$11.3M+38.3% |
| Depreciation & Amortization | $28K-67.4% | $27K-69.0% | $66K-22.4% | $86K0.0% | $86K0.0% | $87K+1.2% | $85K-1.2% | $86K-25.2% |
| Stock-Based Compensation | $1.5M-15.0% | $1.4M-14.9% | N/A | $1.7M-12.7% | $1.8M-66.4% | $1.7M-0.8% | N/A | $2.0M-27.6% |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $0 | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$15.1M-7.9% | N/A |
| Investing Cash Flow | -$3.1M+94.7% | $19.5M+128.2% | -$2.9M-110.4% | $8.6M+291.7% | -$59.2M-8093.6% | $8.5M+162.2% | $27.8M+126.7% | $2.2M+105.8% |
| Financing Cash Flow | $217K+287.1% | -$185K-678.1% | -$196K-167.4% | $134K+153.2% | -$116K-100.5% | $32K-99.2% | $291K+732.6% | -$252K-100.4% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BDTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | N/A | N/A | N/A | N/A | 77.9% | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | 80.8% | N/A | N/A |
| Return on Equity | -10.3%-2.3pp | -8.7%-48.6pp | N/A | -6.7%+9.2pp | -8.0%+10.1pp | 40.0%+57.4pp | N/A | -16.0%+1.2pp |
| Return on Assets | -7.9%-1.6pp | -6.8%-38.9pp | N/A | -5.4%+5.9pp | -6.3%+6.9pp | 32.1%+44.9pp | N/A | -11.3%+2.1pp |
| Current Ratio | 7.28-1.4x | 8.46-0.8x | 8.42+3.5x | 8.94+3.4x | 8.73+1.9x | 9.24+2.2x | 4.92-1.9x | 5.55-4.2x |
| Debt-to-Equity | 0.300.0x | 0.270.0x | 0.27-0.2x | 0.25-0.2x | 0.25-0.1x | 0.25-0.1x | 0.47+0.1x | 0.42+0.1x |
| Asset Turnover | 0.000.0x | 0.00-0.4x | N/A | 0.000.0x | 0.000.0x | 0.40+0.4x | N/A | 0.00 |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Black Diamond Therapeutics, Inc. BDTX | FY2025 | $70.0M | N/A | N/A | $98.8M | 67/100 |
| C4 Therapeutics, Inc. CCCC | FY2025 | $35.9M | -$105.0M | N/A | $340.2M | 65/100 |
| Elicio Therapeutics, Inc. ELTX | FY2025 | N/A | -$39.6M | N/A | $42.3M | — |
| NeOnc Technologies Holdings, Inc. NTHI | FY2025 | $40K | N/A | N/A | $77.8M | — |
| Kyverna Therapeutics, Inc. KYTX | FY2025 | N/A | -$161.3M | N/A | $350.7M | — |
| Nuvectis Pharma, Inc. NVCT | FY2025 | N/A | -$26.4M | N/A | $607.2M | — |
Where Black Diamond Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Black Diamond Therapeutics, Inc.'s annual revenue?
Black Diamond Therapeutics, Inc. (BDTX) reported $70.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
What is Black Diamond Therapeutics, Inc.'s EBITDA?
Black Diamond Therapeutics, Inc. (BDTX) had EBITDA of $12.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Black Diamond Therapeutics, Inc.'s operating margin?
Black Diamond Therapeutics, Inc. (BDTX) had an operating margin of 17.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Black Diamond Therapeutics, Inc.'s operating cash flow?
Black Diamond Therapeutics, Inc. (BDTX) generated $29.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Black Diamond Therapeutics, Inc.'s total assets?
Black Diamond Therapeutics, Inc. (BDTX) had $143.0M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Black Diamond Therapeutics, Inc. spend on research and development?
Black Diamond Therapeutics, Inc. (BDTX) invested $33.6M in research and development during fiscal year 2025.
What is Black Diamond Therapeutics, Inc.'s current ratio?
Black Diamond Therapeutics, Inc. (BDTX) had a current ratio of 8.42 as of fiscal year 2025, which is generally considered healthy.
What is Black Diamond Therapeutics, Inc.'s debt-to-equity ratio?
Black Diamond Therapeutics, Inc. (BDTX) had a debt-to-equity ratio of 0.27 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Black Diamond Therapeutics, Inc.'s P/E ratio?
Black Diamond Therapeutics, Inc. (BDTX) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $98.8M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Black Diamond Therapeutics, Inc.'s price-to-sales ratio?
Black Diamond Therapeutics, Inc. (BDTX) trades at 1.4x sales, its market capitalization divided by revenue of $70.0M revenue, FY2025. The market capitalization is $98.8M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Black Diamond Therapeutics, Inc.'s Altman Z-Score?
Black Diamond Therapeutics, Inc. (BDTX) has an Altman Z-Score of -0.87, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
How financially healthy is Black Diamond Therapeutics, Inc.?
Black Diamond Therapeutics, Inc. (BDTX) scores 67 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.